About ValenzaBio
ValenzaBio is a company based in Bethesda (United States) founded in 2019 was acquired by ACELYRIN in January 2023. ValenzaBio has raised $79.37 million across 1 funding round from investors including Fidelity Investments, Pierre Fabre and ACELYRIN. The company has 17 employees. ValenzaBio operates in a competitive market with competitors including Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
- Headquarter Bethesda, United States
- Employees 17
- SectorsHealthcare
- Website valenzabiotech.com
- Acquired by ACELYRIN (Jan 2023)
- Total Equity Funding$79.37M (USD)
in 1 rounds
- Latest Funding Round$79.37M (USD), Series A
Apr 2021
- InvestorsFidelity Investments
& 5 more
- Employee Count17
- Acquired byACELYRIN
(Jan 2023)
Funding Insights of ValenzaBio
ValenzaBio has successfully raised a total of $79.37M through 1 strategic funding round. The most recent funding activity was a Series A round of $79.37 million completed in April 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $79.37M
- Total Rounds 1
- Last Round Series A — $79.37M
- First Round $79.37M
(Apr 2021)
- Investors Count 5
All 1 funding rounds of ValenzaBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2021 | $79.37M | Series A | – | Fidelity Investments, Ikarian Capital | – |
6 investors in total: 6 institutional.
Investors in ValenzaBio
ValenzaBio has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, Pierre Fabre and ACELYRIN.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment services are offered by Ikarian Capital for various sectors. | – | ikariancapital.com | Dallas, United States | |
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
Long, short, event-driven, and multiple strategies are employed by Citadel. | 1990 | citadel.com | Chicago, United States | |
Pharma, dermo-cosmetics, OTC, and consumer health products are provided. | 1962 | pierre-fabre.com | Castres, France | |
Immunological drug candidates are developed for severe diseases. | 2020 | acelyrin.com | Los Angeles, United States |
Investor details for ValenzaBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of ValenzaBio
3 dated milestones of ValenzaBio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded ValenzaBio is founded.
- Funding First funding round of $79.4M.
- Exit Acquired by ACELYRIN.
Competitors of ValenzaBio
ValenzaBio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, ADMA Biologics, Kymeratx, BioNTech and Generate Biomedicines, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| admabiologics.com | 2005 | Ramsey, United States | $17.55M | 498 | Plasma-based biologics are developed for immune deficiency and infectious diseases. | |
| kymeratx.com | 2016 | Cambridge, United States | $197M | 150 | Small molecule protein degraders are developed for various disorders. | |
| biontech.com | 2008 | Mainz, Germany | $805.99M | 4,530 | Immunotherapeutics for cancer and other diseases are developed. | |
| generatebiomedicines.com | 2018 | Somerville, United States | $643M | 286 | Developer of novel protein-based therapeutics using machine learning and biological engineering | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. | |
| ucb.com | 1928 | Brussels, Belgium | – | 79 | Therapies for immunological and neurological disorders are developed. | |
| veratx.com | 2016 | San Francisco, United States | $196.58M | 46 | Therapeutic solutions for immunological and inflammatory diseases are developed. | |
| cabalettabio.com | 2017 | Radnor, United States | $88.26M | 60 | Developer of CAAR T cells for B cell-mediated autoimmune diseases | |
| apogeetherapeutics.com | 2022 | Waltham, United States | $149M | 91 | Developer of therapeutics for immunological and inflammatory disorders |
Detailed competitors of ValenzaBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Valenzabio
Complete news archive for ValenzaBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to ValenzaBio
10 companies that operate in the same segment as ValenzaBio (Immunology & Cancer Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 | |
Targeted and immune-oncology drugs for cancer treatment are developed. | 2010 | Cambridge, Massachusetts, United States | USD 172 M | – | – | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Targeted therapies for cancer treatment are developed. | 2005 | Waltham, Massachusetts, United States | USD 198.29 M | USD 172.35 M | 270 | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Plasma-based biologics are developed for immune deficiency and infectious diseases. | 2005 | Ramsey, Minnesota, United States | USD 17.55 M | USD 510.17 M | 685 | |
Antibody drugs for cancer treatment are developed. | 2015 | Singapore, Singapore | USD 150 M | – | – | |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | 2003 | United States | USD 171.85 M | USD 102.48 M | 338 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about ValenzaBio
ValenzaBio was founded in 2019 and raised its 1st funding round 2 years after it was founded.
ValenzaBio is headquartered in Bethesda, United States. It is registered at Bethesda, Maryland, United States.
ValenzaBio is a funded company, having raised a total of $79.37M across 1 funding round to date. The company's 1st funding round was a Series A of $79.37M, raised on Apr 2021.
ValenzaBio has 17 employees.
Founded in 2019 and based in Bethesda, United States, treatments for autoimmune and inflammatory diseases are developed by ValenzaBio in the biotechnology sector. Operations center on monoclonal antibodies, with VB119 designed as an IgG1 that binds to the CD-19 B-cell receptor for membranous nephropathy management. VB421 is engineered to bind IGF-1R at sub-50 pM affinity, targeting thyroid eye disease.
ValenzaBio's top competitors include ADMA Biologics, BioNTech and Vera Therapeutics.
ValenzaBio has 6 investors. Key investors include Fidelity Investments, Pierre Fabre, ACELYRIN, Citadel, and Janus Henderson Investors.
Yes. ValenzaBio was acquired by ACELYRIN in January 2023.